Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E. Fajadet J, et al. Among authors: laarman gj. Circulation. 2005 Mar 1;111(8):1040-4. doi: 10.1161/01.CIR.0000156334.24955.B2. Epub 2005 Feb 21. Circulation. 2005. PMID: 15723977 Free article. Clinical Trial.
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Fajadet J, et al. Among authors: laarman gj. Circulation. 2006 Aug 22;114(8):798-806. doi: 10.1161/CIRCULATIONAHA.105.591206. Epub 2006 Aug 14. Circulation. 2006. PMID: 16908773 Clinical Trial.
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Baldus S, Hauptmann KE, Suttorp MJ, Drzewiecki J, Pieper M, Schultheiss HP, Mauri L. Fajadet J, et al. Among authors: laarman gj. EuroIntervention. 2010 Nov;6(5):562-7. doi: 10.4244/EIJV6I5A95. EuroIntervention. 2010. PMID: 21044908
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions.
Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG. Suttorp MJ, et al. Among authors: laarman gj. Circulation. 2006 Aug 29;114(9):921-8. doi: 10.1161/CIRCULATIONAHA.106.613588. Epub 2006 Aug 14. Circulation. 2006. PMID: 16908768 Clinical Trial.
Primary stenting of occluded native coronary arteries II--rationale and design of the PRISON II study: a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions.
Rahel BM, Laarman GJ, Suttorp MJ; PRISON II study investigators. Rahel BM, et al. Among authors: laarman gj. Am Heart J. 2005 Mar;149(3):e1-3. doi: 10.1016/j.ahj.2004.10.027. Am Heart J. 2005. PMID: 15864219
The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697.
Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction). Dirksen MT, et al. Eur Heart J. 2004 Mar;25(5):392-400. doi: 10.1016/j.ehj.2003.12.018. Eur Heart J. 2004. PMID: 15033251 Clinical Trial.
Oral administration of glycine in the prevention of restenosis after coronary angioplasty. A double blind placebo controlled randomized feasibility trial evaluating safety and efficacy of glycine in the prevention of restenosis after angioplasty.
Khan M, Ron Van Der Wieken L, Riezebos RK, Tijssen JG, Kiemeneij F, Slagboom T, Laarman GJ. Khan M, et al. Among authors: laarman gj. Acute Card Care. 2006;8(1):58-64. doi: 10.1080/14628840600643383. Acute Card Care. 2006. PMID: 16720430 Clinical Trial.
118 results